Lu Lu

Lu Lu, Shibo Jiang, Jingying Hu, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A core epitope targeting antibody of SARS-CoV-2

Guisheng Zhong, Suwen Zhao, Lu Lu, 2022, Protein & cell.

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection

Jie Zhou, Lu Lu, Shibo Jiang, 2021, Microbes and Infection.

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein

Lu Lu, Suiyi Tan, Shuwen Liu, 2022, Journal of virology.

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein

Lu Lu, Xingmin Sun, S. Xia, 2022, Cell discovery.

The cytoplasmic domain of influenza M2 protein interacts with caveolin-1.

Lu Lu, Ying-hua Chen, Fan Wu, 2009, Archives of biochemistry and biophysics.

Important Changes in Biochemical Properties and Function of Mutated LLP12 Domain of HIV‐1 gp41

Lu Lu, Ying-hua Chen, Yun Zhu, 2007, Chemical biology & drug design.

Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41.

A. Debnath, A. Katritzky, Hong Lu, 2011, Journal of medicinal chemistry.

A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

Hong Lu, Lu Lu, Shibo Jiang, 2012, Retrovirology.

MERS-CoV spike protein: a key target for antivirals

Lu Lu, Shibo Jiang, Yang Yang, 2017, Expert opinion on therapeutic targets.

Receptor-binding domain-based subunit vaccines against MERS-CoV

Lu Lu, Shibo Jiang, L. Du, 2014, Virus Research.

Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies

D. Dimitrov, K. Yuen, P. Prabakaran, 2014, Journal of Virology.

Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo.

Y. Qiu, S. Curry, Yuan Fang, 2021, Immunity.

The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants

Lu Lu, Qiaoshuai Lan, J. Pu, 2022, Viruses.

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

D. Qu, Y. Wen, Shibo Li, 2021, Cell Reports.

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines

D. Qu, Lu Lu, Shibo Jiang, 2020, Proceedings of the National Academy of Sciences.

A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection.

Lu Lu, Shibo Jiang, Ke Huang, 2016, Microbes and infection.

Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection.

Lu Lu, Shibo Jiang, Yuan Li, 2013, Microbes and infection.

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin

W. Xu, Lu Lu, Shibo Jiang, 2020, Signal Transduction and Targeted Therapy.

dl-Mandelic acid exhibits high sperm-immobilizing activity and low vaginal irritation: A potential non-surfactant spermicide for contraception.

Lu Lu, Shibo Jiang, Jingying Hu, 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Lu Lu, Shibo Jiang, Siliang Feng, 2020, Cell Research.

Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit

D. Qu, Lu Lu, Shibo Jiang, 2020, Virologica Sinica.

Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China

K. Hong, Y. Shao, Lu Lu, 2013, Virology Journal.

The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses

Wei Xu, Lu Lu, Shibo Jiang, 2018, Front. Microbiol..

Development of oncolytic virotherapy: from genetic modification to combination therapy

W. Xu, Lu Lu, Shibo Jiang, 2020, Frontiers of Medicine.

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells

Qiang Zhou, Lu Lu, Shibo Jiang, 2021, Cell Research.

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects

Lu Lu, Shibo Jiang, Lulu Si, 2018, Protein & Cell.

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Y. Wen, Hongzhou Lu, Lu Lu, 2020, medRxiv.

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Y. Wen, Hongzhou Lu, Lu Lu, 2020, medRxiv.

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China

Y. Wen, Hongzhou Lu, Lu Lu, 2020, JAMA internal medicine.

Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator

Lu Lu, S. Xia, Peng Zou, 2019, Viruses.

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Lu Lu, Wei Xu, Shibo Jiang, 2020, Cellular & Molecular Immunology.

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

W. Xu, Lu Lu, Shibo Jiang, 2020, Cellular & Molecular Immunology.

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

Lu Lu, David K Meyerholz, Shibo Jiang, 2015, The Journal of infectious diseases.

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein

Lu Lu, Shan Su, Shibo Jiang, 2014, Virus Research.

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

D. Dimitrov, Lu Lu, Shibo Jiang, 2014, Microbes and Infection.

Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases

W. Xu, Lu Lu, Shibo Jiang, 2020, International journal of molecular sciences.

Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles

Lu Lu, Shibo Jiang, S. Xia, 2017, Antimicrobial Agents and Chemotherapy.

Development of therapeutics for treatment of Ebola virus infection.

Lu Lu, Shibo Jiang, Fei Yu, 2015, Microbes and infection.

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Lu Lu, Wenjie Tan, Qian Wang, 2019, Science Advances.

A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue

Lu Lu, Shibo Jiang, Peng Zou, 2019, Front. Microbiol..

Tactics used by HIV‐1 to evade host innate, adaptive, and intrinsic immunities

W. Xu, Lu Lu, Shibo Jiang, 2013, Chinese medical journal.

Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease

Lu Lu, Shibo Jiang, Robert B. Couch, 2015, Journal of Virology.

Advancements in the development of subunit influenza vaccines.

Lu Lu, Shibo Jiang, L. Du, 2015, Microbes and infection.

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Y. Wen, Lu Lu, Shibo Jiang, 2020, Frontiers in Microbiology.

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

Jie Zhou, Lu Lu, Shuofeng Yuan, 2022, Viruses.

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases

Jie Zhou, Lu Lu, Shibo Jiang, 2021, Acta Pharmaceutica Sinica B.

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

S. Perlman, Lu Lu, Shibo Jiang, 2015, Cellular and Molecular Immunology.

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

W. Xu, Lu Lu, Shibo Jiang, 2020, Cell Research.

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41

Lu Lu, Shibo Jiang, J. Pu, 2019, Viruses.

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein

S. Sidhu, S. Miersch, Lu Lu, 2022, Communications Biology.

Antivirals with common targets against highly pathogenic viruses

Lu Lu, Shibo Jiang, Haitao Yang, 2021, Cell.

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants

Xiaoxu Tian, Zhenlin Yang, Lu Lu, 2021, Signal Transduction and Targeted Therapy.

An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope

Y. Wen, Zhenguo Chen, Jie Zhou, 2021, Protein & Cell.

Fully human single-domain antibodies against SARS-CoV-2

Lu Lu, Shibo Jiang, T. Ying, 2020, bioRxiv.

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

Lu Lu, Shibo Jiang, Weihua Li, 2017, BioMed research international.

Identification of Human Single-Domain Antibodies against SARS-CoV-2

Lu Lu, Shibo Jiang, T. Ying, 2020, Cell Host & Microbe.

SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors

Lu Lu, S. Xia, Jinghe Huang, 2023, Journal of medical virology.

ADS-J1 Inhibits Semen-Derived Amyloid Fibril Formation and Blocks Fibril-Mediated Enhancement of HIV-1 Infection

Lu Lu, Suiyi Tan, Shibo Jiang, 2015, Antimicrobial Agents and Chemotherapy.

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects

Lu Lu, Shibo Jiang, Lulu Si, 2018, Protein & Cell.

Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines

Jie Zhou, Lu Lu, Zezhong Liu, 2022, Journal of medical virology.

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

J. Chan, K. Yuen, Lu Lu, 2022, Cell Research.

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)

Lu Lu, S. Xia, Qiaoshuai Lan, 2021, Cell discovery.

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors

Lu Lu, S. Xia, Yun Zhu, 2023, Emerging microbes & infections.

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

F. Kirchhoff, Jie Zhou, J. Münch, 2021, Signal Transduction and Targeted Therapy.

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains

Lu Lu, Shibo Jiang, S. Xia, 2018, International journal of molecular sciences.

Adenovirus-based vaccines against avian-origin H5N1 influenza viruses

Lu Lu, Shibo Jiang, L. Du, 2014, Microbes and Infection.

Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.

Lu Lu, Shibo Jiang, Qian Wang, 2014, Journal of medicinal chemistry.

Multitargeted drug design strategy for discovery of short-peptide-based HIV-1 entry inhibitors with high potency.

Lu Lu, Chao Wang, F. Yu, 2023, European journal of medicinal chemistry.

Identification of the HIV-1 gp41 Core-binding Motif in the Scaffolding Domain of Caveolin-1*

Xi Chen, Lu Lu, Shibo Jiang, 2007, Journal of Biological Chemistry.

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells

Lu Lu, T. Ying, Yanling Wu, 2022, mBio.

Long‐Acting Protective Ocular Surface by Instilling Adhesive Dual‐Antiviral Nanoparticles

Feng Wu, Lu Lu, Jinyao Liu, 2022, Advanced healthcare materials.

Engineered Trimeric ACE2 Binds and Locks “Three-up” Spike Protein to Potently Inhibit SARS-CoVs and Mutants

Qiang Zhou, Lu Lu, Wei Xu, 2020, bioRxiv.

Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors.

Liang Xu, Jinglai Li, Lu Lu, 2013, Journal of medicinal chemistry.

Immunoengineered adjuvants for universal vaccines against respiratory viruses

Lu Lu, Shibo Jiang, Ji Wang, 2021, Fundamental Research.

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread

Lu Lu, Shibo Jiang, Lu Lu, 2013, Microbes and Infection.

A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome

Lu Lu, Shibo Jiang, T. Ying, 2020, Cellular & Molecular Immunology.

A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses

K. Yuen, Lu Lu, Shibo Jiang, 2017, Nature Communications.

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III

Lu Lu, Shibo Jiang, T. Ying, 2017, Emerging microbes & infections.

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo

Lu Lu, Wanting Wang, Xuanming Yang, 2023, Communications biology.

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket

Lu Lu, Shibo Jiang, Fei Yu, 2013, Viruses.

25‐hydroxycholesterol inhibits human papillomavirus infection in cervical epithelial cells by perturbing cytoskeletal remodeling

Lu Lu, Qian Wang, Shibo Jiang, 2023, Journal of medical virology.

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines

Lu Lu, Shibo Jiang, W. Xu, 2012, Emerging Microbes & Infections.

Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015)

Lu Lu, Weihua Li, Wen Li, 2017, Expert opinion on therapeutic patents.

Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection

S. Huo, Lu Lu, Shibo Jiang, 2021, Journal of medicinal chemistry.

Diterpenoids from Euphorbia lactea and their anti-HIV-1 activity.

Lu Lu, Qun-fang Liu, Yao-yue Fan, 2023, Phytochemistry.

Receptor Binding Domain Based HIV Vaccines

Lu Lu, Shibo Jiang, Qian Wang, 2015, BioMed research international.

Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection

D. Dimitrov, P. Prabakaran, I. Sidorov, 2019, Journal of Virology.

Copper(II) Gluconate Boosts the Anti-SARS-CoV-2 Effect of Disulfiram in vitro

Suwen Zhao, Lu Lu, Wei Xu, 2021, bioRxiv.

Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations

Rongguang Zhang, Lu Lu, Shibo Jiang, 2016, Scientific Reports.

Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat–C-terminal heptad repeat interactions and C-peptides’ anti-HIV activity

Lu Lu, Shibo Jiang, Keliang Liu, 2014, AIDS.

Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket

Lu Lu, Suiyi Tan, Shibo Jiang, 2011, Journal of Virology.

Mutations of Gln 64 in the HIV-1 gp 41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp 41 Pocket

Lu Lu, Suiyi Tan, Ying-hua Chen, 2011 .

Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.

W. Xu, Lu Lu, Shibo Jiang, 2017, Microbes and infection.

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection

Lu Lu, Shibo Jiang, T. Ying, 2021, Molecules.

Testing of Middle East Respiratory Syndrome Coronavirus Replication Inhibitors for the Ability To Block Viral Entry

Lu Lu, Shibo Jiang, Qian Wang, 2014, Antimicrobial Agents and Chemotherapy.

An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene

Lu Lu, Shibo Jiang, T. Ying, 2016, Emerging Microbes & Infections.

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

Y. Liu, Lu Lu, Chao Wang, 2023, Viruses.

Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.

Lu Lu, Bingjie Qin, Lan Xie, 2014, Bioorganic & medicinal chemistry letters.

Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection

Qiang Zhou, Lu Lu, Shibo Jiang, 2020, Cell research.

HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen

Lu Lu, Shibo Jiang, Zhiwu Sun, 2017, Emerging microbes & infections.

A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses

Lu Lu, Shibo Jiang, Qiaoshuai Lan, 2021, Cell & bioscience.

Up or down: where comes Omicron?

Lu Lu, Zezhong Liu, Shibo Jiang, 2022, Cell Research.

Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity

Rongguang Zhang, Lu Lu, Shibo Jiang, 2018, Biochemical and Biophysical Research Communications.

An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood–Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability

Lu Lu, Xingmin Sun, Jianfeng Cai, 2023, ACS central science.

Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor

Lu Lu, Shibo Jiang, Ying-hua Chen, 2010, Journal of Virology.

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies

Lu Lu, S. Xia, Qian Wang, 2023, Biomolecules.

Lymphocyte integrins mediate entry and dysregulation of T cells by SARS-CoV-2

Lu Lu, Jianfeng Chen, G. Ge, 2023, Signal Transduction and Targeted Therapy.

Controlling HIV sexual transmission: a major challenge for China’s new leadership

Lu Lu, Shibo Jiang, Weihua Li, 2013, Cell & Bioscience.

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

Lu Lu, S. Xia, Yun Zhu, 2023, Emerging microbes & infections.

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates

Jie Zhou, Lu Lu, Jinghe Huang, 2023, Proceedings of the National Academy of Sciences of the United States of America.

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein

Lu Lu, Xingmin Sun, S. Xia, 2022, Cell Discovery.

A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity

Lu Lu, Shibo Jiang, Yun Zhu, 2017, AIDS.

A Novel Chimeric Protein-based HIV-1 Fusion Inhibitor Targeting gp41 Glycoprotein with High Potency and Stability*

Hong Lu, Lu Lu, Shibo Jiang, 2011, The Journal of Biological Chemistry.

An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications† †Electronic supplementary information (ESI) available: General materials, methods, and the details. See DOI: 10.1039/c5sc04046a

Lu Lu, Shibo Jiang, Keliang Liu, 2015, Chemical science.

Development and validation of a prognostic model based on immune variables to early predict severe cases of SARS-CoV-2 Omicron variant infection

Lu Lu, S. Xia, Shibo Jiang, 2023, Frontiers in Immunology.

Development of therapeutics for treatment of Ebola virus infection.

Lu Lu, Shibo Jiang, T. Ying, 2015, Microbes and infection.

Putative suppressing effect of IgG Fc-conjugated haemagglutinin (HA) stalk of influenza virus H7N9 on the neutralizing immunogenicity of Fc-conjugated HA head: implication for rational design of HA-based influenza vaccines.

Lu Lu, S. Xia, F. Yu, 2016, The Journal of general virology.

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines

Lu Lu, Shibo Jiang, W. Xu, 2012, Emerging Microbes & Infections.

Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat–C-terminal heptad repeat interactions and C-peptides’ anti-HIV activity

Lu Lu, Shibo Jiang, Keliang Liu, 2014, AIDS.

An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides.

Lu Lu, Shibo Jiang, Ying-hua Chen, 2013, The Journal of antimicrobial chemotherapy.

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread

Lu Lu, Xinling Wang, Shibo Jiang, 2023, Signal transduction and targeted therapy.

Clinical development of antivirals against SARS-CoV-2 and its variants

Jie Zhou, Lu Lu, Qiaoshuai Lan, 2023, Current research in microbial sciences.

Coronavirus Entry Inhibitors.

Lu Lu, Qiaoshuai Lan, Shuai Xia, 2022, Advances in Experimental Medicine and Biology.

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies

Jie Zhou, Lu Lu, Chao Wang, 2023, International journal of molecular sciences.

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)

Lu Lu, Qiaoshuai Lan, Fei Sun, 2021, Cell Discovery.